Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn’s Disease in a Real-Life Setting: Results of a Prospective Multicenter Study in Germany
Open Access
- 18 December 2020
- journal article
- research article
- Published by S. Karger AG in Inflammatory Intestinal Diseases
- Vol. 6 (1), 48-60
- https://doi.org/10.1159/000512159
Abstract
Introduction: Infliximab (IFX) therapy is efficacious for inducing and maintaining symptomatic remission in patients with Crohn’s disease (CD), but whether this benefit results in reduced hospitalization rates and therefore may improve patients’ quality of life in an economically sensible way is conflicting so far. Methods: We conducted a noninterventional, multicenter, open-label, prospective study to evaluate the effect of originator IFX treatment on patient-reported outcomes and disease-related hospitalizations in adult CD patients in Germany treated for the first time with IFX according to label. Results: Two hundred and ninety-four patients were included in the study. We observed a statistically significant reduction in the number of CD-related hospitalizations from the year before baseline (mean 1.00 per patient, SD ± 0.93) to the mean value of the 1st (0.62, SD ± 0.95) and 2nd year (0.32, SD ± 0.75) of the observation period (p < 0.0001). After 3 months of IFX therapy, work productivity and activity increased by an average of 12.6 and 17.1%, respectively. Patient’s clinical outcome was markedly improved as the total CD activity index (CDAI) sum score continuously decreased from baseline to month 24 and the mean score of the total inflammatory bowel disease questionnaire (IBDQ) changed substantially from 141 at baseline to 172 after 24 months of IFX treatment. Additionally, the number of work incapacity days declined. Recently, no new safety issues of IFX have been identified. Conclusion: In this large, prospective, multicenter study on disease-related hospitalization rates, work productivity, capacity for daily activities, and HRQoL in patients with CD, IFX significantly reduces their hospitalization rates and improves work productivity, daily activity, and quality of life over 24 months.Keywords
This publication has 36 references indexed in Scilit:
- Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysisPharmacoepidemiology and Drug Safety, 2011
- Systematic review: the costs of ulcerative colitis in Western countriesAlimentary Pharmacology & Therapeutics, 2010
- The impact of biologics on health-related quality of life in patients with inflammatory bowel diseaseClinical and Experimental Gastroenterology, 2009
- Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's diseaseClinical Therapeutics, 2008
- Costs of Inflammatory Bowel Disease in GermanyPharmacoEconomics, 2006
- Disease outcome of inflammatory bowel disease patients: General outline of a Europe-wide population-based 10-year clinical follow-up studyScandinavian Journal of Gastroenterology, 2006
- The validity and accuracy of the Work Productivity and Activity Impairment questionnaire – irritable bowel syndrome version (WPAI:IBS)Alimentary Pharmacology & Therapeutics, 2004
- Infliximab Maintenance Therapy for Fistulizing Crohn's DiseaseThe New England Journal of Medicine, 2004
- Burden of illness of Crohn’s disease in SpainDigestive and Liver Disease, 2003
- Validity of a Work Productivity and Activity Impairment Questionnaire for Patients with Symptoms of Gastro-Esophageal Reflux Disease (WPAI-GERD)—Results from a Cross-Sectional StudyValue in Health, 2002